SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm
May 11, 2021 11:33 ET | Bragar Eagel & Squire
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:04 ET | Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
September 28, 2020 08:45 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
August 25, 2020 06:30 ET | Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
Harpoon_logo (002).jpg
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
November 21, 2019 04:00 ET | Harpoon Therapeutics; AbbVie Inc.
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Allergan plc (NYSE: AGN) on Behalf of Allergan Shareholders and Encourages Allergan Investors to Contact the Firm
June 26, 2019 16:32 ET | Bragar Eagel & Squire
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Allergan plc (NYSE: AGN) on behalf of Allergan...
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
May 07, 2019 07:23 ET | Aptinyx Inc.
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Voyager Therapeutics Logo.jpg
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
February 22, 2019 08:00 ET | Voyager Therapeutics, Inc.
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1...
Schall Firm Logo 2.jpg
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 20, 2018 12:37 ET | Schall Law
LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...